Five-year follow-up data from the global, phase 2 JULIET (NCT02445248)trial, which evaluated the chimeric antigen receptor (CAR)T-cell therapy tisagenlecleucel (tisa-cel; Kymriah) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback